Navigation Links
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR

Tanespimycin Shown to Have No Effect on QTc Interval

HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- Kosan Biosciences Incorporated today presented safety data from preclinical and clinical studies of its lead Hsp90 inhibitor, tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoring of patients was conducted in four Phase 1 trials of tanespimycin. Cardiac monitoring analyses were conducted in more than 85 patients. Tanespimycin was found to have no effect on QTc interval (a measure of the heart's electrical cycle) in these patients based on data analyses from manually read ECGs in a central laboratory or by site cardiologists.

"The analyses performed by cardiac specialists confirm that tanespimycin had no effect on QTc interval," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Moreover, it is clear from these analyses that two previously reported incidents of possible QTc interval effects in studies of tanespimycin conducted by the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) were based on artifactual QTc prolongation data from automated computer reads and were unrelated to drug product. Our Hsp90 inhibitors have been administered to more than 600 patients in trials conducted by Kosan and by the NCI and the safety profile of the compound class has been well characterized. With the anticipated initiation of our TIME registration program for tanespimycin in patients with multiple myeloma, and with plans underway to advance second- generation alvespimycin into later-stage trials in patients with HER2-positive metastatic breast cancer, we look forward to further characterizing the efficacy and safety profiles of these exciting and potentially important new cancer therapies."

The data from the cardiac monitoring analyses were presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) in a p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:9/30/2014)... -- Georgia-Pacific Professional is a leading provider of hygienic ... range of away from home applications. Building on ... including hospitals, long-term care facilities, surgical centers and ... products and solutions to the dental community. ... control in the dental office," said Sean ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... 23 OrbusNeich today announced that six-month follow-up ... and efficacy of the company,s Genous Bio-engineered R ... the treatment of de novo coronary artery disease. ... University of Ulm, Germany, principal investigator of the ...
... DEERFIELD, Ill. and LONDON, Sept. 23 Following today’s ... and the European Medicines Agency (EMA) for rosiglitazone in ... and Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s ... medications, and to the millions of people living with ...
Cached Medicine Technology:OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease 2OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... WASHINGTON Legislation passed in 2003 to slow the ... government to treat Medicare patients has had no meaningful ... of researchers in the Journal of Clinical Oncology ... of outpatient chemotherapy to treat colorectal and lung cancers, ... oncologists prescribe those drugs following the implementation of the ...
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... by certified nutrition specialist and best-selling author Mike Geary that ... and totally transform their body into a fat-burning machine in ... Michaels, prompting an investigative review. , “In our culture ... it can be hard to decipher what is really fact ...
(Date:9/30/2014)... NY (PRWEB) September 30, 2014 ... hosted its annual “In Celebration” gala, honoring three ... nonprofit’s mission of striving to provide extraordinary and ... families facing a serious or life-limiting illness. , ... Club in Rye, NY and recognized William (Bill) ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... levels influence heart disease risk , , SUNDAY, Jan. 13 ... influence the risk of heart disease, have been identified ... three countries. , "I would predict that some of ... said the study,s senior author, Goncalo Abecasis, an associate ...
... Driving Global Breast Cancer Leader,s Promise ... Cancer Forever, ATLANTA, Jan. 12 Hala Moddelmog, president ... leader in the fight to end breast,cancer forever, today was ... Awards event in Atlanta with a ,High Heels in High,Places, ...
... Mandate Weakens After SEIU Contributes $450K to Prop ... ... "mean" or people will not be compelled to buy health insurance under the,Massachusetts ... financial projections for a similar plan pending in,California., As reported in the ...
... Department of,Environmental Protection is helping with efforts to ... 42-inch pipe ruptured Thursday evening between the city,s ... Island wastewater treatment plant.,The estimated 10 million gallons ... the treatment plant are, temporarily, being discharged into ...
... and lifestyle are at root of reduced risk, , , FRIDAY, Jan. ... your blood may reduce your risk of stroke, new research suggests. ... in their blood had a 42 percent lower risk of stroke ... is in the January issue of The American ...
... With a continued focus on,quality and efficiency ... focus on opportunities for streamlining processes to,maximize ... for,manufacturing organizations, the majority of the benchmark ... could provide several,worthwhile benefits, as found in ...
Cached Medicine News:Health News:Seven New Cholesterol Genes Discovered 2Health News:Seven New Cholesterol Genes Discovered 3Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:MA Proponent of Health Insurance Mandate Says 'Mean' Penalties Needed to Force People to Buy Insurance 2Health News:Vitamin C May Play Role in Stroke Prevention 2Health News:Vitamin C May Play Role in Stroke Prevention 3Health News:Manufacturing Organizations Identify Efficiencies in Maintenance Functions 2
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
10 mm wide tip....
Large. Double-ended. 3 mm pointed end and 5 mm angled end....
9 mm wide tip. Designated most popular model or size....
Medicine Products: